The global respiratory diseases drugs market, one of the segments
of healthcare industry. During the historic period it grew at a compound annual
growth rate (CAGR) of around 6.5%. This was mainly due to the increased air
pollution which will lead to increased respiratory diseases.
For the forecasted period, the respiratory market size is
expected to be over $70 billion by 2021, growing at a CAGR of nearly 6.5%. The
growth rate for forecasted period is higher when compared to the historic
period. This is mainly attributed to the rise in global air pollution levels which
will lead to higher number of respiratory diseases thus driving the respiratory
drugs market.
Find TBRC’s report on the Respiratory Drugs market:
Anti-Asthmatics And COPD Drugs was the largest segment in
the respiratory drugs market accounting for 65% of the market. This segment
includes companies that produce drugs that can be used to relieve the frequency
of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal
awakenings. Some of the major anti-asthmatics and COPD drugs include antimuscarinics,
corticosteroids, leukotriene inhibitors, xanthines, albuterol (Vospire ER),
levalbuterol (Xopenex), ipratropium (Atrovent).xxxiv The large size of this
segment was due to increasing number of patients of asthma and COPD caused by
tobacco smoking and air pollution.
Download a sample report:
About The Business Research Company.
The Business Research Company is a
Business Intelligence Company which excels in company, market and consumer
research. It has offices in the UK, the US and India and a network of trained
researchers in 15 countries globally.
Contact Information.
The Business Research Company
Europe: +44
207 1930 708
Asia: +91
8897263534
Americas: +1
315 623 0293
Follow us on Linkedin: https://in.linkedin.com/company/the-business-research-company
